ESR1 and endometritis: Results show that compared to women who did not express antibody to PmpA, rates of elevated WBC (40.0% versus 23.5%), increased CRP (66.7% versus 46.2%), increased ESR (40.0% versus 31.4%), endometritis (100% versus 60.7%), and UGTI (75.0% versus 46.8%) were higher among women who expressed antibody to PmpA (Table 2).